Jazz Pharmaceuticals
JAZZ
376 hedge funds and large institutions have $9.65B invested in Jazz Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 120 increasing their positions, 103 reducing their positions, and 35 closing their positions.
163% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 35
100% more call options, than puts
Call options by funds: $117M | Put options by funds: $58.7M
19% more capital invested
Capital invested by funds: $8.13B → $9.65B (+$1.52B)
17% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 103
16% more funds holding
Funds holding: 323 → 376 (+53)
3.24% more ownership
Funds ownership: 90.14% → 93.38% (+3.2%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$279M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$117M |
| 3 |
State Street
Boston,
Massachusetts
|
+$86.5M |
| 4 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$82.8M |
| 5 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
+$74.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$371M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$79.5M |
| 3 |
SIG
Senator Investment Group
New York
|
-$76.5M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$52.2M |
| 5 |
Goldman Sachs
New York
|
-$42.4M |
JAZZ Hedge Fund Activity: Q2 2018 in Review
376 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2018, worth a combined $9.65B — up 19% from $8.13B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new JAZZ positions and 35 closed out — a net gain of 57 holders — while 120 added to existing stakes and 103 trimmed.
The largest buyer was BlackRock, adding an estimated $279M. The largest seller was Putnam Investments, cutting an estimated $371M.
- 376 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2018, up from 323 in Q1 2018.
- Funds reported $9.65B of Jazz Pharmaceuticals stock for Q2 2018, up 19% quarter-over-quarter.
- 92 funds opened new Jazz Pharmaceuticals positions in Q2 2018 and 35 closed out, a net change of +57 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $279M added.
- The largest Jazz Pharmaceuticals seller in Q2 2018 was Putnam Investments, an estimated $371M sold.
Based on aggregated 13F filings for Q2 2018.